Dermata Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRMA research report →
About the company
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis.
- CEO
- Gerald T. Proehl
- IPO
- 2021
- Employees
- 8
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $913.29K
- P/E
- -0.25
- P/S
- 0.00
- P/B
- 0.81
- EV/EBITDA
- 0.84
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -127.91%
- ROIC
- -114.77%
- Revenue
- $0 · 0.00%
- Net Income
- $-7,558,557 · 38.49%
- EPS
- $-8.16 · 89.84%
- Op Income
- $-7,773,598
- FCF YoY
- -69393.82%
- 52W High
- $8.00
- 52W Low
- $1.10
- 50D MA
- $1.26
- 200D MA
- $2.25
- Beta
- 0.69
- Avg Volume
- 75.19K
Get TickerSpark's AI analysis on DRMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Scott Kathleen D. | sell | 11 |
| Feb 17, 26 | Bedoya-Toro Munera Maria E | buy | 1,000 |
| Jan 2, 26 | PROEHL GERALD T | other | 37,500 |
| Jan 2, 26 | HALE DAVID F | other | 2,500 |
| Jan 2, 26 | WIERENGA WENDELL | other | 2,500 |
| Jan 2, 26 | Bedoya-Toro Munera Maria E | other | 9,000 |
| Jan 2, 26 | Scott Kathleen D. | other | 2,500 |
| Jan 2, 26 | Nardo Christopher J. | other | 18,000 |
| Jan 2, 26 | Sandler Andrew Seth | other | 2,500 |
| Jan 2, 26 | Van Hoose Kyri K. | other | 18,000 |
Our DRMA coverage
Recent articles, reports, and earnings notes.
No research on DRMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRMA report →Similar companies
Peers in the same neighborhood.